Publications

2008

Rutherford SC, Andemariam B, Philips SM, Elstrom RL, Chadburn A, Furman RR, et al. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leuk Lymphoma. 2008;49(4):719-26.
Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik J-, Ying H, et al. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A. 2008;105(49):19372-7.
Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008;68(21):8899-907.
Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, et al. Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol. 2008;21(6):676-84.
Gaertner WB, Hagerman GF, Finne CO, Alavi K, Jessurun J, Rothenberger DA, et al. Fistula-associated anal adenocarcinoma: good results with aggressive therapy. Dis Colon Rectum. 2008;51(7):1061-7.
Mandeville JA, Neto BS, Vanni AJ, Smith GL, Rieger-Christ KM, Zeheb R, et al. P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells. BJU Int. 2008;102(11):1707-14.
Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res. 2008;14(19):6033-41.
Li Y, Kang YS, Dai C, Kiss LP, Wen X, Liu Y. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol. 2008;172(2):299-308.
Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008;15(1):191-205.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700